PDE5 Inhibition and Cognitive Function

Kuritzky, Louis
August 2011
Internal Medicine Alert;8/15/2011 Supplement 2, p119
The article presents a study that investigates the impact of Udenafil, otherwise known as PDE5 inhibitor on cognition, somatization and erection on patients with erectile dysfunction (ED).


Related Articles

  • Broadening Perspectives on Maintaining Healthy Erectile Function. Kurltzky, Louise // Neurology Alert;Jun2012, Vol. 30 Issue 10, p11 

    The article discusses research on maintaining healthy erectile function, with a reference to a study by D. R. Meldrum et al published in a 2012 issue of the "International Journal of Impotence Research."

  • IMPROVING INTIMACY. Magill-Lewis, Jillene // Drug Topics;1/21/2002, Vol. 146 Issue 2, p33 

    Focuses on treatment options for sexual problems in the U.S. Number of U.S. people who suffered sexual dysfunction; Effective treatments for erectile dysfunction; Differences of sexual dysfunction from other disorders.

  • First pill for male impotence approved in US. Charatan, Fred // BMJ: British Medical Journal (International Edition);04/11/98, Vol. 316 Issue 7138, p1112 

    Details the approval given by the United States Food and Drug Administration to a drug that will treat erectile dysfunction. Number of men suffering from erectile dysfunction; Implications of the approval on Pfizer; How the drug was discovered for the disorder; How the drug works.

  • One good rub. GERACI, RON // Men's Health;Mar99, Vol. 14 Issue 2, p61 

    Introduces the penile erection gel called Topiglan developed at Boston University. Impotence drug it contains; Where it should be applied; Comment from Doctor Irwin Goldstein.

  • NexMed Has Positive Trial for Sexual Disfunction Treatment.  // Biotech Business;Oct99, Vol. 12 Issue 10, p2 

    Reports on the results of the first phase of the clinical trial on NexMed Incorporated's Femprox topical treatment for female sexual dysfunction.

  • Impotence pill. Vizard, Frank; Stover, Dawn // Popular Science;Jan98, Vol. 252 Issue 1, p30 

    Focuses on medicinal treatments for impotence. Problems with erectile dysfunction; The drug sildenafil; Increased blood flow; Mention of the drug phentolamine.

  • Vardenafil: A Viewpoint by Hartmut Porst. Porst, H. // Drugs & Aging;2002, Vol. 19 Issue 3, p228 

    Focuses on pharmacodynamic properties of vardenafil. Specificity for phosphodiesterase 5; Tolerability of vardenafil.

  • Vardenafil. Ormrod, D.; Easthope, S.E.; Figgitt, D.P. // Drugs & Aging;2002, Vol. 19 Issue 3, p217 

    â–´ Vardenafil selectively inhibits phosphodiesterase type 5 (PDE5), an enzyme which hydrolyses cyclic guanosine monophosphate in the cavernosum tissue of the penis. Inhibition of PDE5 results in increased arterial blood flow leading to enlargement of the corpus cavernosum. Because of the...

  • The problem most men won't talk about. Reznichek, Carol Gainor; Reznichek, Richard; Collins, Helen Lippman // RN;Mar90, Vol. 53 Issue 3, p28 

    Discusses several treatments for impotence or erectile dysfunction. Physiological responses that produce an erection; Causes of impotence; Diagnosis of the sexual disorder.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics